Children and psychotropic medication: What role should advocacy counseling play?

Journal of Counseling and Development

Volumn 82, Issue 3, 2004, Pages 337-343

  Ingersoll, R Elliott ^a,b   Bauer, Ann ^a   Burns, Laura ^b  

^a Department of Counseling ^*  (United States)

^b CLEVELAND STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 3543016125     PISSN: 07489633     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1556-6678.2004.tb00319.x     Document Type: Review

References (57)

1. American Academy of Child and Adolescent Psychiatry. (1997). Practice parameters for the assessment and treatment of children and adolescents with Bipolar Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 36(Suppl. 2), 157-176.
2. American Counseling Association. (1995). Code of ethics and standards of practice. Alexandria, VA: Author.
3. American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th ed., text revision). Washington, DC: Author.
4. Andreasen, N. (2001). Brave new brain. New York: Oxford.
5. Antonuccio, D. O., Danton, W. G., DeNelsky, G. Y., Greenberg, R. P., & Gordon, J. S. (1999). Raising questions about antidepressants. Psychotherapy and Psychosomatics, 68, 3-14.
6. Binder, G. M. (1999). Pharmaceutical provisions of the FDA Modernization Act of 1997: One year and counting. Current Opinion in Biotechnology, 10, 303-306.
7. Bodenheimer, T. (2000). Uneasy alliance: Clinical investigators and the pharmaceutical industry. The New England Journal of Medicine, 342, 1539-1544.
8. Borzo, G. (1997). Consumer drug ads booming: FDA reviews restrictions. Amednews.com. Retrieved January 28, 2002, from http://www.ama-assn.org/amednews/ 1997/pick_97/pick0210.htm
9. Bostic, J. Q., Wilens, T., Spencer, T., & Biederman, J. (1997). Juvenile mood disorders and office psychopharmacology. Pediatric Clinics of North America, 44, 1487-1503.
10. Bradley, C. (1937). The behavior of children receiving Benzedrine. American Journal of Orthopsychiatry, 9, 577-585.
11. Breggin, P. R. (1997). Brain disabling treatments in psychiatry. New York: Springer.
12. Brody, A. L., Saxena, S., Stoessel, P., Gillies, P., Fairbanks, L. A., Alborzian, S., et al. (2001). Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: Preliminary findings. Archives of General Psychiatry, 58, 631-640.
13. Colbert, T. C. (2002, June). Drugs or psychotherapy: What's the answer? Symposium conducted in Beechwood, OH.
14. Connors, C. K. (1972). Pharmacotherapy. In H. C. Quay & J. S. Werry (Eds.), Psychopathological disorders of childhood (pp. 316-347). New York: Wiley.
15. Coyle, J. T. (2000). Psychotropic drug use in very young children. Journal of the American Medical Association, 283, 1059-1060.
16. Dodd, C. (2001). Dodd and Dewine introduce bill to provide better drug safety for children. Retrieved January 28, 2002, from www.senate.gov/~dodd/ press/Releases/01/0504.htm
17. Emslie, G. J., Walkup, J.T., Pliszka, S. R., & Ernst, M. (1999). Nontricyclic antidepressants: Current trends in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 517-528.
18. Eriksen, K. (1999). Counselor advocacy: A qualitative analysis of leaders' perceptions, organizational activities, and advocacy documents. Journal of Mental Health Counseling, 21, 33-49.
19. Express Scripts. (2001). Fact sheet: Express scripts drug trend report. Retrieved November 14, 2001, from http://www.express-scripts.com/
20. Findling, R. L., McNamara, N. K., Branicky, L. A., Schluchter, M. D., Lemon, E., & Blumer, J. L. (2000). A double-blind pilot study of Risperidone in the treatment of Conduct Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 39, 509-516.
21. Fisher, S., & Greenberg, R. P. (1997). From placebo to panacea: Putting psychiatric drugs to the test. New York: Wiley.
22. Gabbard, G. O. (2001). Mind and brain in psychiatric treatment. In G. O. Gabbard (Ed.), Treatments of psychiatric disorders (3rd ed., pp. 3-20). Washington, DC: American Psychiatric Association.
23. Gadow, K. D. (1997). An overview of three decades of research in pediatric psychopharmacoepidemiology. Journal of Child and Adolescent Psychopharmacology, 7, 219-236.
24. Gadow, K. D. (1999). Prevalence of drug therapy. In J. S. Werry & M. G. Aman (Eds.), Practitioner's guide to psychoactive drugs for children and adolescents (2nd ed., pp. 51-69). New York: Plenum.
25. Greenhill, L. L. (1998). Childhood attention deficit hyperactivity disorder: Pharmacological treatments. In P. Nathan & J. German (Eds.), A guide to treatments that work (pp. 42-64). New York: Oxford.
26. Healy, D. (1997). The antidepressant era. Cambridge, MA: Harvard University Press.
27. Healy, D., & Doogan, D. P. (Eds.). (1996). Psychotropic drug development: Social, economic, and pharmacological aspects. London: Chapman & Hall.
28. Hegarty, J., Baldessarini, R. J., Tohen, M., Waternaux, C., & Oepen, G. (1994). One hundred years of schizophrenia: A meta-analysis of the outcome literature. American Journal of Psychiatry, 151, 1409-1416.
29. Hollon, M. F. (1999). Direct-to-consumer marketing of prescription drugs: Creating consumer demand. Journal of the American Medical Association, 281, 1227-1228.
30. Holmer, A. F. (1999). Direct to consumer prescription drug advertising builds bridges between patients and physicians. Journal of the American Medical Association, 281, 380-382.
31. IMS [Intercontinental Marketing Services] Health. (2000). Too much attention paid to ADHD? IMS Health Monthly Midas. Retrieved November 11, 2001, from www.imshealth.com
32. Ingersoll, R. E. (2000). Teaching a course in psychopharmacology to counselors: Justification, structure, and methods. Counselor Education and Supervision, 40, 58-69.
33. Ingersoll, R. E., & Previts, L. C. (2001). Prevalence of adult disorders. In E. Welfel & R. E. Ingersoll (Eds.), The mental health desk reference (pp. 155-161). New York: Wiley.
34. Jensen, P. S., Bhatara, V. S., Vitiello, B., Hoagwood, K., Feil, M., & Burke, L. (1999). Psychoactive medication practices for US children: Gaps between research and clinical practice. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 557-565.
35. Julien, R. M. (2001). A primer of drug action: A concise, nontechnical guide to the actions, uses, and side effects of psychoactive drugs (9th ed.). New York: Worth.
36. Khan, A., Leventhal, R. M., Khan, S. R., & Brown, W. A. (2002). Severity of depression and response to antidepressants and placebo: An analysis of the Food and Drug Administration database. Journal of Clinical Psychopharmacology, 22, 40-45.
37. Kiselica, M. S., & Robinson, M. (2001). Bringing advocacy counseling to life: The history, issues, and human dramas of social justice work in counseling. Journal of Counseling & Development, 79, 387-397.
38. Lilly Pharmaceuticals (Producer). (1998). Depression: The road to recovery [Promotional video].
39. Littrell, J., & Ashford, J. (1995). Is it proper for psychologists to discuss medications with clients? Professional Psychology: Research and Practice, 238, 238-244.
40. Martin, S. D., Martin, E., Rai, S. S., Richardson, M. A., & Royall, R. (2001). Brain blood flow changes in depressed patients treated with interpersonal psychotherapy or venlafaxine hydrochloride: Preliminary findings. Archives of General Psychiatry, 58, 641-648.
41. Minde, K. (1998). The use of psychotropic medications in preschoolers: Some recent developments. Canadian Journal of Psychiatry, 43, 571-575.
42. Olson, C., Drummond, R., Cook, D., Dickersin, K., Fanagin, A., Hogan, J., et al. (2002). Publication bias in editorial decision making. Journal of the American Medical Association, 287, 2825-2828.
43. Patterson, L. E. (1996). Strategies for improving medication compliance. Essential Psychopharmacology, 1, 70-79.
44. Pediatric Pharmacotherapy. (1995). The FDA approval process. Retrieved January 23, 2002, from http://www.people.virginia.edu/~smb4v/pedpharm/v1n11. html.
45. Pelham, W. E., Jr. (1993). Guest editor's comments: Recent developments in pharmacological treatment for child and adolescent mental health problems. School Psychology Review, 22, 158-161.
46. Rappley, M. D., Mullan, P. B., Alvarez, F. J., Eneli, I. U., Wang, J., & Gardner, J. C. (1999). Diagnosis of attention-deficit/hyperactivity disorder and use of psychotropic medication in very young children. Archives of Pediatric and Adolescent Medicine, 153, 1039-1045.
47. Riddle, M. A., Labellarte, M. J., & Walkup, J.T. (1998). Pediatric psychopharmacology: Problems and prospects. Journal of Child and Adolescent Psychopharmacology, 8, 87-97.
48. Rushton, J. L., & Whitmire, J.T. (2001). Pediatric stimulant and selective serotonin reuptake inhibitor prescription trends: 1992 to 1998. Archives of Pediatric and Adolescent Medicine, 155, 560-565.
49. RxList. (2003). The top 200 prescriptions for 2002 by number of US prescriptions dispensed. Retrieved June 10, 2004, from http://www.rxlist.com/ top200.htm
50. Safer, D. J., & Krager, J. M. (1988). A survey of medication treatment for hyperactive/inattentive students. Journal of the American Medical Association, 260, 2256-2258.
51. Scott-Levin Pharmaceutical Consulting Firm. (2000). Drug development for children: On the grow. Pharmaceutical Quarterly. Retrieved January 28, 2002, from http://www.quintiles.corn/products_and_services/informatics/scott_levin/ press_releases/press_release/print_friendly/1,1255,56,00.html
52. Solov, D. (2001, November 18). Ethical dilemmas surround kids' drugs. The Cleveland Plain Dealer, pp. A1, A8.
53. Weller, E. (1999, May). Pediatric psychopharmacology. Paper presented at the meeting of the American Psychiatric Association, Washington, DC.
54. Werry, J. S. (1999). Introduction: A guide for practitioners, professionals, and public. In J. S. Werry & M. G. Aman (Eds.), Practitioner's guide to psychoactive drugs for children and adolescents (2nd ed., pp. 3-22). New York: Plenum.
55. Wozniak, J., Biederman, J., Spencer, T., & Wilens, T. (1997). Pediatric psychopharmacology. In A. J. Gelenberg & E. L. Bassuk (Eds.), The practitioner's guide to psychoactive drugs (4th ed., pp. 385-415). New York: Plenum.
56. Zito, J. M., Safer, D. J., dosReis, S., Gardner, J. F., Boles, M., & Lynch, F. (2000). Trends in prescribing psychotropic medications to preschoolers. Journal of the American Medical Association, 283, 1025-1030.
57. Zito, J. M., Safer, D. J., dosReis, S., Gardner, J. F., Magder, L., Soeken, K., et al. (2003). Psychotropic practice patterns for youth: A 10-year perspective. Archives of Pediatric and Adolescent Medicine, 157, 17-25.